LBA38Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
Choueiri, T.K., Hessel, C., Halabi, S., Sanford, B., Hahn, O., Michaelson, M.D., Walsh, M., Olencki, T., Picus, J., Small, E.J., Dakhil, S., Scheffold, C., George, D.J., Morris, M.J.Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx440.032
Date:
September, 2017
File:
PDF, 56 KB
english, 2017
File converter
More search results
More benefits 
